Thank you forpointing it out: I missed it, and its nice typo. Maybe the RE expected the strong oppositionthat they have rightly received. And indeed, why not employ such expensive servicesto support one’s conflicts of interest, and make the punters pay for it? There’sno downside. I wonder if the PS get a success fee as wellas a base fee.
*As you say, …and of course voting in favour of Boards'/REs' desired resolutions, and against resolutions sponsored by minority investors.
YES this in unfortunaterecent import from USA. I have encountered such firms 3 or 4 timesin the last 2 years in OZ, including most recently on trying to persuade me tovotes for the abysmal HUM part-merger deal with Latitude, promoted by the majoritydirectors. It fortunately collapsed when the board saw that proxy votes were trendingabout 4-1 against, despite the efforts of these PR firms to phone investors andspin the deal as fabulous and necessary, when it was exactly the opposite. Anothercase of boards acting against shareholders interests, and making you pay for thisPR.
Your link is pertinent> Proxy Solicitation &Governance Advisory Overview
Proxy Solicitation is key to good shareholder communications[sic ie Board propaganda], whether ahead of a shareholder meeting, as part of a governance roadshow or linked to a corporate action or M&A.
We adviseour clients on their shareholder relationships, how to avoid conflict, and ifconflict is inevitable, how to navigate to a positive result.
Activist Tracking Identify and track activist investorsand their supporters in real-time…… [and nobble them].
- Forums
- ASX - By Stock
- CD3
- Ann: Supplementary Explanatory Memorandum
CD3
cd private equity fund iii
Add to My Watchlist
0.00%
!
$1.18

Ann: Supplementary Explanatory Memorandum, page-16
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
$1.18 |
Change
0.000(0.00%) |
Mkt cap ! $84.99M |
Open | High | Low | Value | Volume |
$1.19 | $1.19 | $1.18 | $66.37K | 56.25K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 11360 | $1.17 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.18 | 500 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 11360 | 1.170 |
3 | 21248 | 1.150 |
1 | 1854 | 1.125 |
2 | 10000 | 1.120 |
1 | 6144 | 1.110 |
Price($) | Vol. | No. |
---|---|---|
1.180 | 500 | 1 |
1.220 | 5151 | 1 |
1.235 | 18269 | 1 |
1.240 | 2546 | 1 |
1.250 | 21450 | 1 |
Last trade - 10.31am 25/06/2025 (20 minute delay) ? |
Featured News
CD3 (ASX) Chart |
The Watchlist
PTX
PRESCIENT THERAPEUTICS LIMITED
James McDonnell, CEO
James McDonnell
CEO
SPONSORED BY The Market Online